Skip to main content
  • More from ADA
    • Diabetes Care
    • Clinical Diabetes
    • Diabetes Spectrum
    • ADA Standards of Medical Care in Diabetes
    • ADA Scientific Sessions Abstracts
    • BMJ Open Diabetes Research & Care
  • Subscribe
  • Log in
  • My Cart
  • Follow ada on Twitter
  • RSS
  • Visit ada on Facebook
Diabetes

Advanced Search

Main menu

  • Home
  • Current
    • Current Issue
    • Online Ahead of Print
    • ADA Scientific Sessions Abstracts
  • Browse
    • By Topic
    • Issue Archive
    • Saved Searches
    • ADA Scientific Sessions Abstracts
    • Diabetes COVID-19 Article Collection
    • Diabetes Symposium 2020
  • Info
    • About the Journal
    • About the Editors
    • ADA Journal Policies
    • Instructions for Authors
    • Guidance for Reviewers
  • Reprints/Reuse
  • Advertising
  • Subscriptions
    • Individual Subscriptions
    • Institutional Subscriptions and Site Licenses
    • Access Institutional Usage Reports
    • Purchase Single Issues
  • Alerts
    • E­mail Alerts
    • RSS Feeds
  • Podcasts
    • Diabetes Core Update
    • Special Podcast Series: Therapeutic Inertia
    • Special Podcast Series: Influenza Podcasts
    • Special Podcast Series: SGLT2 Inhibitors
    • Special Podcast Series: COVID-19
  • Submit
    • Submit a Manuscript
    • Submit Cover Art
    • ADA Journal Policies
    • Instructions for Authors
    • ADA Peer Review
  • More from ADA
    • Diabetes Care
    • Clinical Diabetes
    • Diabetes Spectrum
    • ADA Standards of Medical Care in Diabetes
    • ADA Scientific Sessions Abstracts
    • BMJ Open Diabetes Research & Care

User menu

  • Subscribe
  • Log in
  • My Cart

Search

  • Advanced search
Diabetes
  • Home
  • Current
    • Current Issue
    • Online Ahead of Print
    • ADA Scientific Sessions Abstracts
  • Browse
    • By Topic
    • Issue Archive
    • Saved Searches
    • ADA Scientific Sessions Abstracts
    • Diabetes COVID-19 Article Collection
    • Diabetes Symposium 2020
  • Info
    • About the Journal
    • About the Editors
    • ADA Journal Policies
    • Instructions for Authors
    • Guidance for Reviewers
  • Reprints/Reuse
  • Advertising
  • Subscriptions
    • Individual Subscriptions
    • Institutional Subscriptions and Site Licenses
    • Access Institutional Usage Reports
    • Purchase Single Issues
  • Alerts
    • E­mail Alerts
    • RSS Feeds
  • Podcasts
    • Diabetes Core Update
    • Special Podcast Series: Therapeutic Inertia
    • Special Podcast Series: Influenza Podcasts
    • Special Podcast Series: SGLT2 Inhibitors
    • Special Podcast Series: COVID-19
  • Submit
    • Submit a Manuscript
    • Submit Cover Art
    • ADA Journal Policies
    • Instructions for Authors
    • ADA Peer Review
Commentary

Exploring the Promise of Resveratrol: Where Do We Go From Here?

  1. Jill P. Crandall⇑ and
  2. Nir Barzilai
  1. Diabetes Research and Training Center and Institute for Aging Research, Albert Einstein College of Medicine, Bronx, New York
  1. Corresponding author: Jill P. Crandall, jill.crandall{at}einstein.yu.edu.
Diabetes 2013 Apr; 62(4): 1022-1023. https://doi.org/10.2337/db12-1788
PreviousNext
  • Article
  • Figures & Tables
  • Info & Metrics
  • PDF
Loading

Resveratrol (3,5,4’-trihydroxystilbene), a plant-derived polyphenol and activator of the mammalian sirtuin, SIRT1, has demonstrated promising effects on glucose metabolism in rodent models (1). However, despite the widespread use of resveratrol as a nutritional supplement and the many health claims made on its behalf, data from human studies are extremely limited. Here, we explore why, in contrast to many studies in mammalian models, the article by Poulsen et al. (2) in this issue of Diabetes reports that chronic high doses of resveratrol have no demonstrable metabolic effects.

Interest in resveratrol has skyrocketed in recent years, initially from its association with the health benefits of red wine (the “French paradox”) and its in vitro anticancer activity (3). Subsequent reports demonstrated that it activates sirtuins and extends the life span of lower organisms (“calorie restriction mimetic”), including rodents (4). Studies in vitro show that resveratrol enhances insulin-stimulated glucose uptake in skeletal muscle, liver, and adipocytes (5,6) and stimulates insulin secretion via inhibition of β-cell KATP channels (7). These observations have been confirmed in vivo in several animal models, including aging, diet-induced obesity, and diabetic (db/db) mice (4,8–10). Importantly, key metabolic effects of resveratrol can be monitored in relevant tissues (muscle, fat, and liver), thus providing critical insight into mechanisms. These effects include increased mitochondrial biogenesis and oxidative phosphorylation, increased SIRT1, AMP kinase and PGC-1α activation, and decreased inflammatory markers in tissues.

Available data from human resveratrol studies have largely been limited to short-term pharmacokinetic or toxicology studies. However, recently a few studies exploring the cardiometabolic effects of resveratrol have been published (11–13). Timmers et al. (11) reported improvement in a variety of metabolic parameters in a small group of obese middle-aged men treated with resveratrol (150 mg/day) for 30 days. These included increased metabolic rate, improved insulin sensitivity, and reductions in hepatic fat and markers of inflammation. In skeletal muscle, mitochondrial function was increased, as were activated AMPK and levels of SIRT1 and PGC-1α. Another study (12) reported improved glucose tolerance and insulin sensitivity in older adults with impaired glucose tolerance (IGT) at doses of 1,000–2,000 mg/day for 4 weeks. These human studies, in a wide range of doses, have been consistent with observations from animal models in showing the positive effects of resveratrol on glucose metabolism.

In the study by Poulsen et al. (2), obese men (mean age ∼35 years) were treated with resveratrol 1,500 mg/day or placebo for 4 weeks. Surprisingly, a comprehensive and scientifically rigorous set of procedures designed to assess effects on in vivo insulin sensitivity, energy expenditure, and body composition and on in vitro analysis of tissues, including gene expression, AMPK phosphorylation, inflammation, and oxidative stress, failed to show any evidence of an effect. This study has a number of strengths, including the performance of a wide array of metabolic tests, application of “gold standard” methodology (euglycemic clamp, gene arrays, NMR spectroscopy, etc.), and the selection of a moderate-to-high resveratrol dose that would be most likely to demonstrate benefit, if such exists. However, the failure of these exhaustive tests to detect even a hint of resveratrol effect suggests the possibility of one or more fundamental limitations in the study design. First, evidence suggests that resveratrol works in metabolically compromised states (4,8–10). The relatively young subjects in this study were obese, but were not selected on the basis of glucose intolerance and, according to HOMA-IR (a test with known limitations), were at most mildly insulin resistant. As pointed out by the authors, these individuals may have been “too metabolically healthy” to benefit from resveratrol. Other studies in young lean (14) or nonobese middle-aged subjects with normal glucose tolerance (15) also failed to demonstrate significant metabolic effects of low-to-moderate resveratrol doses. Likewise, studies in lean rodents treated with resveratrol have also failed to detect any benefit on metabolism or life span with resveratrol (16,17). Second, questions remain about the quality and bioavailability of resveratrol. Commercially available resveratrol preparations, considered as food supplements, are not subject to the regulatory oversight required for pharmaceuticals. In a separate pilot study, the authors provide evidence that the resveratrol preparation used in their study can be absorbed and detected in the plasma following oral administration, but plasma levels were not measured during the main study. The presence of urinary resveratrol metabolites provides reassurance that some resveratrol was consumed, but in the presence of overwhelmingly negative results, specific quantification of plasma levels would be helpful. Lastly, since resveratrol is rapidly cleared from plasma and has a t1/2 of ∼2.5 h (18), it is possible that the metabolic tests were performed too long after the last resveratrol administration, resulting in lack of effect or possibly even a “rebound” worsening of metabolic parameters.

The many challenges to the translation of resveratrol’s promising preclinical data to careful human studies were recently reviewed (19) and include issues related to dosing, toxicity, drug interactions, lack of the U.S. Food and Drug Administration (FDA) oversight, and inadequate funding. Despite initial enthusiasm, resveratrol has largely been abandoned by the pharmaceutical industry, although the reasons (scientific vs. economic) have not been made public and results of some completed clinical trials were never published. In this context, a well-done but ultimately negative study can be highly informative and can advance the field. One lesson from this experience is that future studies should be conducted in subjects with a defined metabolic defect, particularly the patient population for which the compound might have clinical utility. The issue of appropriate resveratrol dose also requires additional study. Doses used in animal (5–500 mg/kg/day) and human studies (5–5,000 mg/day) have varied widely, and not enough is known about the dose-response relationship. Price et al. (20) recently demonstrated that different doses of resveratrol can elicit different responses, with lower resveratrol doses (∼30 mg/kg/day) increasing SIRT1-dependent AMPK phosphorylation and higher doses (∼300 mg/kg/day) working via a SIRT1-independent mechanism (Fig. 1). Whether this has relevance to the so far inconsistent findings in human resveratrol studies needs to be explored. Other unknown factors that may affect resveratrol efficacy, such as role of race, sex, and age, also need further study. We predict that in metabolically compromised individuals (e.g., insulin resistance or aging) effects of resveratrol may be seen in numerous tissues and will be associated with clinically apparent metabolic benefits.

FIG. 1.
  • Download figure
  • Open in new tab
  • Download powerpoint
FIG. 1.

Potential mechanisms for low- vs. high-dose resveratrol. IMCL, intramyocellular lipids; PKC, protein kinase C.

ACKNOWLEDGMENTS

No potential conflicts of interest relevant to this article were reported.

Footnotes

  • See accompanying original article, p. 1186.

  • © 2013 by the American Diabetes Association.

Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. See http://creativecommons.org/licenses/by-nc-nd/3.0/ for details.

REFERENCES

  1. ↵
    1. Baur JA,
    2. Sinclair DA
    . Therapeutic potential of resveratrol: the in vivo evidence. Nat Rev Drug Discov 2006;5:493–506pmid:16732220
    OpenUrlCrossRefPubMedWeb of Science
  2. ↵
    1. Poulsen MM,
    2. Vestergaard PF,
    3. Clasen BF,
    4. et al
    . High-dose resveratrol supplementation in obese men: an investigator-initiated, randomized, placebo-controlled clinical trial of substrate metabolism, insulin sensitivity, and body composition. Diabetes 2013;62:1186–1195pmid:23193181
    OpenUrlAbstract/FREE Full Text
  3. ↵
    1. Jang M,
    2. Cai L,
    3. Udeani GO,
    4. et al
    . Cancer chemopreventive activity of resveratrol, a natural product derived from grapes. Science 1997;275:218–220pmid:8985016
    OpenUrlAbstract/FREE Full Text
  4. ↵
    1. Barger JL,
    2. Kayo T,
    3. Vann JM,
    4. et al
    . A low dose of dietary resveratrol partially mimics caloric restriction and retards aging parameters in mice. PLoS ONE 2008;3:e2264pmid:18523577
    OpenUrlCrossRefPubMed
  5. ↵
    1. Sun C,
    2. Zhang F,
    3. Ge X,
    4. et al
    . SIRT1 improves insulin sensitivity under insulin-resistant conditions by repressing PTP1B. Cell Metab 2007;6:307–319pmid:17908559
    OpenUrlCrossRefPubMedWeb of Science
  6. ↵
    1. Breen DM,
    2. Sanli T,
    3. Giacca A,
    4. Tsiani E
    . Stimulation of muscle cell glucose uptake by resveratrol through sirtuins and AMPK. Biochem Biophys Res Commun 2008;374:117–122pmid:18601907
    OpenUrlCrossRefPubMedWeb of Science
  7. ↵
    1. Chen WP,
    2. Chi TC,
    3. Chuang LM,
    4. Su MJ
    . Resveratrol enhances insulin secretion by blocking K(ATP) and K(V) channels of beta cells. Eur J Pharmacol 2007;568:269–277pmid:17573071
    OpenUrlCrossRefPubMed
  8. ↵
    1. Do GM,
    2. Jung UJ,
    3. Park HJ,
    4. et al
    . Resveratrol ameliorates diabetes-related metabolic changes via activation of AMP-activated protein kinase and its downstream targets in db/db mice. Mol Nutr Food Res 2012;56:1282–1291pmid:22715031
    OpenUrlCrossRefPubMed
    1. Um JH,
    2. Park SJ,
    3. Kang H,
    4. et al
    . AMP-activated protein kinase-deficient mice are resistant to the metabolic effects of resveratrol. Diabetes 2010;59:554–563pmid:19934007
    OpenUrlAbstract/FREE Full Text
  9. ↵
    1. Baur JA,
    2. Pearson KJ,
    3. Price NL,
    4. et al
    . Resveratrol improves health and survival of mice on a high-calorie diet. Nature 2006;444:337–342pmid:17086191
    OpenUrlCrossRefPubMedWeb of Science
  10. ↵
    1. Timmers S,
    2. Konings E,
    3. Bilet L,
    4. et al
    . Calorie restriction-like effects of 30 days of resveratrol supplementation on energy metabolism and metabolic profile in obese humans. Cell Metab 2011;14:612–622pmid:22055504
    OpenUrlCrossRefPubMedWeb of Science
  11. ↵
    1. Brasnyó P,
    2. Molnár GA,
    3. Mohás M,
    4. et al
    . Resveratrol improves insulin sensitivity, reduces oxidative stress and activates the Akt pathway in type 2 diabetic patients. Br J Nutr 2011;106:383–389pmid:21385509
    OpenUrlCrossRefPubMed
  12. ↵
    1. Crandall JP,
    2. Oram V,
    3. Trandafirescu G,
    4. et al
    . Pilot study of resveratrol in older adults with impaired glucose tolerance. J Gerontol A Biol Sci Med Sci 2012;67:1307–1312pmid:22219517
    OpenUrlAbstract/FREE Full Text
  13. ↵
    1. Ghanim H,
    2. Sia CL,
    3. Abuaysheh S,
    4. et al
    . An antiinflammatory and reactive oxygen species suppressive effects of an extract of Polygonum cuspidatum containing resveratrol. J Clin Endocrinol Metab 2010;95:E1–E8pmid:20534755
    OpenUrlCrossRefPubMedWeb of Science
  14. ↵
    1. Yoshino J,
    2. Conte C,
    3. Fontana L,
    4. et al
    . Resveratrol supplementation does not improve metabolic function in nonobese women with normal glucose tolerance. Cell Metab 2012;16:658–664pmid:23102619
    OpenUrlCrossRefPubMedWeb of Science
  15. ↵
    1. Turrens JF,
    2. Lariccia J,
    3. Nair MG
    . Resveratrol has no effect on lipoprotein profile and does not prevent peroxidation of serum lipids in normal rats. Free Radic Res 1997;27:557–562pmid:9455691
    OpenUrlCrossRefPubMedWeb of Science
  16. ↵
    Miller RA, Harrison DE, Astle CM, et al. Rapamycin, but not resveratrol or simvastatin, extends life span of genetically heterogeneous mice. J Gerontol A Biol Sci Med Sci 2011;66:191–201
  17. ↵
    1. la Porte C,
    2. Voduc N,
    3. Zhang G,
    4. et al
    . Steady-state pharmacokinetics and tolerability of trans-resveratrol 2000 mg twice daily with food, quercetin and alcohol (ethanol) in healthy human subjects. Clin Pharmacokinet 2010;49:449–454pmid:20528005
    OpenUrlCrossRefPubMed
  18. ↵
    1. Smoliga JM,
    2. Vang O,
    3. Baur JA
    . Challenges of translating basic research into therapeutics: resveratrol as an example. J Gerontol A Biol Sci Med Sci 2012;67:158–167pmid:21746739
    OpenUrlPubMedWeb of Science
  19. ↵
    1. Price NL,
    2. Gomes AP,
    3. Ling AJ,
    4. et al
    . SIRT1 is required for AMPK activation and the beneficial effects of resveratrol on mitochondrial function. Cell Metab 2012;15:675–690pmid:22560220
    OpenUrlCrossRefPubMedWeb of Science
PreviousNext
Back to top
Diabetes: 62 (4)

In this Issue

April 2013, 62(4)
  • Table of Contents
  • About the Cover
  • Index by Author
Sign up to receive current issue alerts
View Selected Citations (0)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word about Diabetes.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Exploring the Promise of Resveratrol: Where Do We Go From Here?
(Your Name) has forwarded a page to you from Diabetes
(Your Name) thought you would like to see this page from the Diabetes web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Exploring the Promise of Resveratrol: Where Do We Go From Here?
Jill P. Crandall, Nir Barzilai
Diabetes Apr 2013, 62 (4) 1022-1023; DOI: 10.2337/db12-1788

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Add to Selected Citations
Share

Exploring the Promise of Resveratrol: Where Do We Go From Here?
Jill P. Crandall, Nir Barzilai
Diabetes Apr 2013, 62 (4) 1022-1023; DOI: 10.2337/db12-1788
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • ACKNOWLEDGMENTS
    • Footnotes
    • REFERENCES
  • Figures & Tables
  • Info & Metrics
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • Lifting the Veil on the “Phosphate Flush,” a Cryptic Phenomenon of Experimental Pancreatic Islet Physiology
  • Window of Opportunity: Targeting ANGPTL4 Improves Triglyceride Levels in Maternal Obesity During Pregnancy
  • New Antidiabetes Agent Targeting Both Mitochondrial Uncoupling and Pyruvate Catabolism: Two Birds With One Stone
Show more Commentary

Similar Articles

Navigate

  • Current Issue
  • Online Ahead of Print
  • Scientific Sessions Abstracts
  • Collections
  • Archives
  • Submit
  • Subscribe
  • Email Alerts
  • RSS Feeds

More Information

  • About the Journal
  • Instructions for Authors
  • Journal Policies
  • Reprints and Permissions
  • Advertising
  • Privacy Policy: ADA Journals
  • Copyright Notice/Public Access Policy
  • Contact Us

Other ADA Resources

  • Diabetes Care
  • Clinical Diabetes
  • Diabetes Spectrum
  • Scientific Sessions Abstracts
  • Standards of Medical Care in Diabetes
  • BMJ Open - Diabetes Research & Care
  • Professional Books
  • Diabetes Forecast

 

  • DiabetesJournals.org
  • Diabetes Core Update
  • ADA's DiabetesPro
  • ADA Member Directory
  • Diabetes.org

© 2021 by the American Diabetes Association. Diabetes Print ISSN: 0012-1797, Online ISSN: 1939-327X.